Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies....
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD
Target Price
The average target price of PPGN.SW is 36 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell